** Shares of biopharmaceutical group HUTCHMED (China) Ltd 0013.HK jump 9.7% to HK$26, their highest since April 2
** Stock on course for third consecutive session of gains
** HUTCHMED and Іnnovent Biologics 1801.HK say in a joint statement that China National Medical Products Administration (NMPA) has accepted for review the New Drug Application for the combination of fruquintinib and sintilimab for treatment of renal cell carcinoma in kidney cancer
** Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly LLY.N
** Sintilimab is co-developed and co-commercialized by Іnnovent and Eli Lilly
** Hong Kong's healthcare index .HSCIH falls 1.6%, Hang Seng Biotech Index .HSHKBIO drops 1.8%
** YTD, HUTCHMEd stock up 5.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。